Javier de la Serna

9.3k total citations · 2 hit papers
90 papers, 2.8k citations indexed

About

Javier de la Serna is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Javier de la Serna has authored 90 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Hematology, 42 papers in Genetics and 34 papers in Pathology and Forensic Medicine. Recurrent topics in Javier de la Serna's work include Chronic Lymphocytic Leukemia Research (37 papers), Lymphoma Diagnosis and Treatment (33 papers) and Acute Myeloid Leukemia Research (21 papers). Javier de la Serna is often cited by papers focused on Chronic Lymphocytic Leukemia Research (37 papers), Lymphoma Diagnosis and Treatment (33 papers) and Acute Myeloid Leukemia Research (21 papers). Javier de la Serna collaborates with scholars based in Spain, United States and Italy. Javier de la Serna's co-authors include Miguel Á. Sanz, Marcos González, Pau Montesinos, José D. González, Salut Brunet, Chelo Rayón, Juan Bergua, Giuseppe Milone, Bob Löwenberg and Concha Rivas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Javier de la Serna

84 papers receiving 2.8k citations

Hit Papers

Venetoclax–Rituximab in Relapsed or Refractory Chronic Ly... 2018 2026 2020 2023 2018 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    2018 595 citations John F. Seymour, Thomas J. Kipps et al. profile →
  2. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    2020 252 citations Paolo Ghia, Andrzej Pluta et al. Journal of Clinical Oncology profile →

Peers

Javier de la Serna
Sherry Pierce United States
Katsuji Shinagawa Japan
Michael J. Barnett Canada
J. A. Copplestone United Kingdom
Ryuichi Kamiyama Japan
Emmanuel C. Besa United States
Po Dunn Taiwan
Marzia Varettoni Italy
Jan Samuelsson Sweden
Catherine C. Coombs United States
Sherry Pierce United States
Javier de la Serna
Citations per year, relative to Javier de la Serna Javier de la Serna (= 1×) peers Sherry Pierce

Countries citing papers authored by Javier de la Serna

Since Specialization
Citations

This map shows the geographic impact of Javier de la Serna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier de la Serna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier de la Serna more than expected).

Fields of papers citing papers by Javier de la Serna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier de la Serna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier de la Serna. The network helps show where Javier de la Serna may publish in the future.

Co-authorship network of co-authors of Javier de la Serna

This figure shows the co-authorship network connecting the top 25 collaborators of Javier de la Serna. A scholar is included among the top collaborators of Javier de la Serna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier de la Serna. Javier de la Serna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Asín, María Asunción Pérez‐Jacoiste, Javier de la Serna, Ana Pérez‐Ayala, et al.. (2025). Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review. Open Forum Infectious Diseases. 12(12). ofaf691–ofaf691.
2.
Ricapito, I., et al.. (2024). Tritium transport modelling in Europe: Current status, multi-physics integration and proposal of material property data. Fusion Engineering and Design. 203. 114458–114458. 1 indexed citations
3.
Fernández, Iván, Iole Palermo, F.R. Urgorri, et al.. (2024). Progress in design and experimental activities for the development of an advanced breeding blanket. Nuclear Fusion. 64(5). 56029–56029. 4 indexed citations
4.
5.
6.
Cabrero, Mónica, Lucía López‐Corral, Isidro Jarque, et al.. (2024). Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial. Bone Marrow Transplantation. 59(3). 359–365. 1 indexed citations
7.
Kater, Arnon P., Rosemary Harrup, Thomas J. Kipps, et al.. (2023). MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematological Oncology. 41(S2). 239–242. 8 indexed citations
8.
Jurczak, Wojciech, Andrzej Pluta, Małgorzata Wach, et al.. (2021). Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 393–393. 15 indexed citations
9.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 38(25). 2849–2861. 252 indexed citations breakdown →
10.
11.
12.
Scarfò, Lydia, Mattias Mattsson, Aliki Xochelli, et al.. (2016). Ex Vivo Lymph Node Native Microenvironment Assay Shows Novel Antiproliferative Activity For Idelalisib And Ibrutinib On Cll Cells. Haematologica. 101. 426–426. 1 indexed citations
13.
Ferrá, Christelle, Jaime Sanz, Miguel Ángel Díaz, et al.. (2014). Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leukemia & lymphoma. 56(3). 656–662. 33 indexed citations
14.
Casado, Luis Felipe, Florinda Gilsanz, Marcos González, et al.. (2011). Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica. Gaceta Sanitaria. 25(4). 274–281. 3 indexed citations
15.
16.
Giraldo, Pilar, Pilar Irún, Pilar Alfonso, et al.. (2010). Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Molecules and Diseases. 46(1). 115–118. 26 indexed citations
17.
Rivero, Ana, Inmaculada Rapado, José Francisco Tomás, et al.. (2010). Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma. Leukemia Research. 35(4). 431–437. 4 indexed citations
18.
Tallman, Martin S., Benjamin Brenner, Javier de la Serna, et al.. (2005). Meeting report. Leukemia Research. 29(3). 347–351. 37 indexed citations
19.
Gilsanz, F., Javier de la Serna, Luis Moltó, & Melchor Álvarez‐Mon. (1996). Hemolytic anemia in chronic large granular lymphocytic leukemia of natural killer cells: Cytotoxicity of natural killer cells against autologous red cells is associated with hemolysis. Transfusion. 36(5). 463–466. 17 indexed citations
20.
Serna, Javier de la, et al.. (1988). IMPROVEMENT IN THE ERYTHROPOIESIS OF CHRONIC HAEMODIALYSIS PATIENTS WITH DESFERRIOXAMINE. The Lancet. 331(8593). 1009–1011. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sherry Pierce Breakdown of academic impact, for papers by Katsuji Shinagawa Breakdown of academic impact, for papers by Michael J. Barnett Breakdown of academic impact, for papers by J. A. Copplestone Breakdown of academic impact, for papers by Ryuichi Kamiyama Breakdown of academic impact, for papers by Emmanuel C. Besa Breakdown of academic impact, for papers by Po Dunn Breakdown of academic impact, for papers by Marzia Varettoni Breakdown of academic impact, for papers by Jan Samuelsson Breakdown of academic impact, for papers by Catherine C. Coombs
Rankless by CCL
2026